ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1909

Corticosteroids with or Without Hyaluronic Acid Injections in the Treatment of Trapeziometacarpal (TMC) Osteoarthritis : The Randomised Multicentre RHIZ’ART Trial Study Protocol

Grégoire Cormier1, Amelie Denis2, CHARLES LESKE3, Stephane Varin1, Jerome Dimet4, Lucie Planche1 and Benoit Le Goff5, 1CHD Vendee, La Roche Sur Yon, France, 2CH Le Mans, Le Mans, France, 3Hospital, Cholet, France, 4CH Mont de Marsan, Mont de Marsan, France, 5CHU Nantes, Nantes, France

Meeting: ACR Convergence 2022

Keywords: Cartilage Degradation, clinical trial, corticosteroids, grip strength, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Osteoarthritis – Clinical Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Trapeziometacarpal osteoarthritis is highly prevalent (affects 10 to 25% of people). Treatment modalities consist of non-pharmacological and pharmacological measures, including either corticosteroid or hyaluronic acid (HA) injections. Both types of injections appear to be efficacious but with different response patterns, the corticosteroids having a rapid analgesic whereas the HA giving a delayed but sustained action over time. Although widely performed in clinical practice, there are still controversies on the interest of the association of these 2 treatments in a single injection on pain and function in the short and long term. Our hypothesis was that the association of steroid and HA would be superior to steroid alone on TMC osteoarthritis pain.

The goal of this study was to compare the effect on pain at 3 months of corticosteroids injections performed with or without HA in patients with TMC osteoarthritis.

Methods: This was a multicenter prospective, placebo-controlled, double-blinded, randomized study. We included patients with pain at the thumb base (confirmer by X-ray) resistant to medical therapy with a mean pain VAS ≥ 4 at activity for over 3 months. Patients were treated with intra-articular ultrasound-guided injection with steroids followed by placebo or steroids followed by HA . The evaluators and patients were blinded to the treatment group. The primary outcome was the VAS pain during activity at 3 months. Secondary outcomes were evolution of VAS pain at rest and during activities, evolution of functional scale and grip strength at 1 month, 6 et 12 months. Change from baseline in VAS pain, Cochin score and grip strength were analysed using a linear mixed model.

Results: We included 150 patients, mean age 62 (+/- 9) years, 123 females (83 %). The median BMI was 26.9 (+/- 5.6). The injection could be performed in all patients, partially in 16% of them. We notified infrequent side effects (3 in AH group, 7 in placebo) with minor impact. Our primary outcome was met as pain VAS during activity, decreased significantly more in the HA+steroid group at 3 months. Change from baseline in VAS pain during activity was significantly greater in the HA group (-26.5) versus in the placebo group (-16.6), p=0.023.

The difference was already significant at M1 but without difference after. Change from baseline in VAS pain during activity was -31.2, -14.6, -11.3 in the HA+steroïd group and -23.7, -14.8, -11.5 at M1, M6 and M12. Pain at rest also showed a trend but not significant difference. We did not find significant differences in function at any time point. Concerning the strength, there was no difference. The need for a new injection was higher in the steroid group: 15 versus 9 ; without significative difference. Only 5 patients underwent surgery after one year follow-up (3 and 2 patients respectively).

Conclusion: Our study shows that the injection of HA and steroids leads to a significant improvement in pain during activity compared to the injection of steroid alone at 3 months. Surprisingly the effect of HA does not last after 3 months as we would initially have expected. In view of these results, intra-articular injection of HA and steroids could be recommended in the treatment of TMC osteoarthritis.

Supporting image 1


Disclosures: G. Cormier, None; A. Denis, None; C. LESKE, None; S. Varin, None; J. Dimet, None; L. Planche, None; B. Le Goff, None.

To cite this abstract in AMA style:

Cormier G, Denis A, LESKE C, Varin S, Dimet J, Planche L, Le Goff B. Corticosteroids with or Without Hyaluronic Acid Injections in the Treatment of Trapeziometacarpal (TMC) Osteoarthritis : The Randomised Multicentre RHIZ’ART Trial Study Protocol [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/corticosteroids-with-or-without-hyaluronic-acid-injections-in-the-treatment-of-trapeziometacarpal-tmc-osteoarthritis-the-randomised-multicentre-rhizart-trial-study-protocol/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/corticosteroids-with-or-without-hyaluronic-acid-injections-in-the-treatment-of-trapeziometacarpal-tmc-osteoarthritis-the-randomised-multicentre-rhizart-trial-study-protocol/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology